This section includes information and resources about Stroke Prevention in Atrial Fibrillation (AF) for journalists: Boehringer Ingelheim press releases, background information, related press kits and a collection of images and videos. For additional information please visit Newshome.
First patients enrolled in study to evaluate dabigatran etexilate after PCI with stenting
U.S. FDA grants Breakthrough Therapy Designation to Pradaxa® (dabigatran etexilate) specific investigational antidote- For media outside of the U.S., the UK & Canada only
New Pradaxa® clinical study to explore practical management of patients with atrial fibrillation undergoing ablation- For media outside of the U.S., the UK & Canada only
Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate) litigation
Antidote for rapid reversal of Pradaxa® (dabigatran etexilate) progresses into next stage of clinical investigation with study in patients
The Education Hub on Newshome offers the latest information regarding